Jaguar Health, Inc. (JAGX): Price and Financial Metrics

Jaguar Health, Inc. (JAGX): $4.70

0.19 (+4.21%)

POWR Rating

Component Grades













Add JAGX to Watchlist
Sign Up

Industry: Biotech



in industry

JAGX Stock Summary

  • JAGX has a market capitalization of $8,733,349 -- more than approximately merely 2.62% of US stocks.
  • The volatility of JAGUAR HEALTH INC's share price is greater than that of 99.96% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for JAGX comes in at -279.58% -- higher than that of merely 1.94% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to JAGUAR HEALTH INC, a group of peers worth examining would be IQ, VREX, BAND, VIAV, and PEAR.
  • JAGX's SEC filings can be seen here. And to visit JAGUAR HEALTH INC's official web site, go to

JAGX Valuation Summary

  • In comparison to the median Healthcare stock, JAGX's price/sales ratio is 46.34% lower, now standing at 1.1.
  • JAGX's price/sales ratio has moved NA NA over the prior 94 months.

Below are key valuation metrics over time for JAGX.

Stock Date P/S P/B P/E EV/EBIT
JAGX 2023-01-20 1.1 3.4 -0.2 -0.8
JAGX 2023-01-19 1.1 3.4 -0.2 -0.8
JAGX 2023-01-18 1.2 3.6 -0.2 -0.8
JAGX 2023-01-17 1.2 3.7 -0.2 -0.8
JAGX 2023-01-13 1.3 3.8 -0.3 -0.8
JAGX 2023-01-12 1.3 4.0 -0.3 -0.9

JAGX Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 578.75%.
  • Its 2 year net income to common stockholders growth rate is now at -30.63%.
  • Its 2 year net cashflow from operations growth rate is now at -68.91%.
Over the past 67 months, JAGX's revenue has gone up $9,850,213.

The table below shows JAGX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 10.776 -35.604 -54.186
2022-06-30 8.256 -36.507 -53.858
2022-03-31 5.72 -35.957 -58.572
2021-12-31 4.335 -34.97 -52.595
2021-09-30 4.832 -30.108 -49.646
2021-06-30 6.975 -23.595 -45.725

JAGX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • JAGX has a Quality Grade of C, ranking ahead of 26.4% of graded US stocks.
  • JAGX's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
  • VYGR, MDVL, and NERV are the stocks whose asset turnover ratios are most correlated with JAGX.

The table below shows JAGX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.128 0.596 -2.417
2021-03-31 0.211 0.673 -4.961
2020-12-31 0.250 0.651 109.795
2020-09-30 0.232 0.611 7.457
2020-06-30 0.182 0.479 28.507
2020-03-31 0.143 0.282 -249.492

JAGX Price Target

For more insight on analysts targets of JAGX, see our JAGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.50 Average Broker Recommendation 1.25 (Strong Buy)

JAGX Stock Price Chart Interactive Chart >

Price chart for JAGX

JAGX Price/Volume Stats

Current price $4.70 52-week high $66.75
Prev. close $4.51 52-week low $4.45
Day low $4.45 Volume 311,500
Day high $4.77 Avg. volume 433,534
50-day MA $7.74 Dividend yield N/A
200-day MA $17.95 Market Cap 9.08M

Jaguar Health, Inc. (JAGX) Company Bio

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

JAGX Latest News Stream

Event/Time News Detail
Loading, please wait...

JAGX Latest Social Stream

Loading social stream, please wait...

View Full JAGX Social Stream

Latest JAGX News From Around the Web

Below are the latest news stories about JAGUAR HEALTH INC that investors may wish to consider to help them evaluate JAGX as an investment opportunity.

Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the required procedure of registering the source of the active pharmaceutical ingredient (API) of crofelemer with the Agenzia Italiana Del Farmaco (AIFA), the Italian Medicines Agency, has been successfully completed. Resultingly, batches of crofelemer API manufactured by Milan, Italy-based Indena S.P.A.

Yahoo | January 25, 2023

Is Jaguar Health (JAGX) Stock Really Up 6,800%?

Jaguar Health (JAGX) stock is on the move Monday as investors seek answers to its massive 6,800% gain this morning.

William White on InvestorPlace | January 23, 2023

Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the board of directors has been established for Magdalena Biosciences, Inc., the joint venture recently formed by Jaguar and Filament Health Corp. (NEO:FH, OTCQB:FLHLF) to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults.

Yahoo | January 23, 2023

Jaguar Health Reports Voting Results from January 2023 Special Meeting of Stockholders

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders (the "Special Meeting") held on January 20, 2023 and announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-75, on Monday, January 23, 2023 (the "Effective Date") in order to support the Company's compliance

Yahoo | January 20, 2023

Jaguar Health to Present at Lytham Partners Investor Select Conference on January 31st

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on Tuesday, January 31, 2023 Lisa Conte, Jaguar's president, founder, and CEO, will present at the virtual Lytham Partners Investor Select Conference.

Yahoo | January 20, 2023

Read More 'JAGX' Stories Here

JAGX Price Returns

1-mo -25.40%
3-mo -55.14%
6-mo -75.61%
1-year -91.10%
3-year -97.26%
5-year -99.98%
YTD -27.89%
2022 -91.64%
2021 -57.46%
2020 1.75%
2019 -95.00%
2018 -89.10%

Continue Researching JAGX

Here are a few links from around the web to help you further your research on Jaguar Health Inc's stock as an investment opportunity:

Jaguar Health Inc (JAGX) Stock Price | Nasdaq
Jaguar Health Inc (JAGX) Stock Quote, History and News - Yahoo Finance
Jaguar Health Inc (JAGX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8156 seconds.